FDA Launches Expanded Drug Quality Testing Program
FDA has launched a new drug quality surveillance initiative designed to test more marketed products, detect potential manufacturing quality problems earlier and use the findings to guide inspections and regulatory enforcement.
The Enhanced Approach for Sampling and Testing (EAST) combines rapid screening technologies with conventional laboratory testing to expand surveillance across more manufacturers, therapeutic classes and geographic regions, including domestic and foreign manufacturing facilities, according to the agency.
Under the program, FDA says it will purchase drug samples directly from retail pharmacies and wholesale distributors, allowing the agency to evaluate products actually available to American patients.
Testing will focus on three critical quality attributes: identity, to verify the correct active pharmaceutical ingredient; purity, to identify impurities; and potency, to determine whether products contain the appropriate amount of active ingredient. Samples requiring additional evaluation will undergo confirmatory testing using established, validated analytical methods, including methods described in the United States Pharmacopeia.
FDA said the approach is intended to substantially expand surveillance coverage within existing resource constraints while maintaining the analytical standards necessary for regulatory decisions.
"The EAST initiative gives us an enhanced way to monitor drug quality across an increasingly complex global supply chain," said CDER Office of Pharmaceutical Quality director Michael Kopcha.
The agency said results will help identify potential quality risks, determine whether regulatory action is warranted, and prioritize future inspections.
FDA plans to publish findings through its Drug Quality Sampling and Testing Programs webpage.